Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop-Reference-Cited by-同舟云学术

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Published:2019-05-22 Issue:1 Volume:7 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Bedognetti Davide, ,Ceccarelli Michele,Galluzzi Lorenzo,Lu Rongze,Palucka Karolina,Samayoa Josue,Spranger Stefani,Warren Sarah,Wong Kwok-Kin,Ziv Elad,Chowell Diego,Coussens Lisa M.,De Carvalho Daniel D.,DeNardo David G.,Galon Jérôme,Kaufman Howard L.,Kirchhoff Tomas,Lotze Michael T.,Luke Jason J.,Minn Andy J.,Politi Katerina,Shultz Leonard D.,Simon Richard,Thórsson Vésteinn,Weidhaas Joanne B.,Ascierto Maria Libera,Ascierto Paolo Antonio,Barnes James M.,Barsan Valentin,Bommareddy Praveen K.,Bot Adrian,Church Sarah E.,Ciliberto Gennaro,De Maria Andrea,Draganov Dobrin,Ho Winson S.,McGee Heather M.,Monette Anne,Murphy Joseph F.,Nisticò Paola,Park Wungki,Patel Maulik,Quigley Michael,Radvanyi Laszlo,Raftopoulos Harry,Rudqvist Nils-Petter,Snyder Alexandra,Sweis Randy F.,Valpione Sara,Zappasodi Roberta,Butterfield Lisa H.,Disis Mary L.,Fox Bernard A.,Cesano Alessandra,Marincola Francesco M.

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-019-0602-4.pdf

Reference178 articles.

1. Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6(1):8.

2. Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL, et al. Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer. 2017;81:116–29.

3. Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930–40.

4. The Society for Immunotherapy of Cancer (SITC) - The Cancer Immune Responsiveness Task Force. https://www.sitcancer.org/research/immune-responsiveness .

5. Lu R, Turan T, Samayoa J, Marincola FM. Cancer immune resistance: can theories converge? Emerging Topics Life Sci. 2017;1(5):411–9.

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing vaccine development against Opisthorchis viverrini: A synergistic integration of omics technologies and advanced computational tools;Frontiers in Pharmacology;2024-07-15

2. 5,7,4′‐Trimethoxyflavone triggers cancer cell PD‐L1 ubiquitin–proteasome degradation and facilitates antitumor immunity by targeting HRD1;MedComm;2024-06-27

3. Toll-like receptors in breast cancer immunity and immunotherapy;Frontiers in Immunology;2024-06-06

4. Single-cell RNA-seq reveals T cell exhaustion and immune response landscape in osteosarcoma;Frontiers in Immunology;2024-04-02

5. Shifting the paradigm: engaging multicellular networks for cancer therapy;Journal of Translational Medicine;2024-03-12